Cagrilintide 10mg
Cagrilintide is a synthetic long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic β-cells. It acts as a non-selective amylin receptor agonist, binding primarily to calcitonin receptors and associated receptor activity-modifying proteins (RAMPs).
In preclinical studies, Cagrilintide has shown potent effects on:
Appetite suppression via central satiety pathways
Slowing gastric emptying and enhancing postprandial fullness
Body weight regulation through energy balance modulation
Synergistic activity with GLP-1 receptor agonists in metabolic studies
Its extended half-life and unique receptor activity profile make it valuable in metabolic and obesity research, particularly when combined with GLP-1 analogs like semaglutide or liraglutide.
Cagrilintide is a synthetic long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic β-cells. It acts as a non-selective amylin receptor agonist, binding primarily to calcitonin receptors and associated receptor activity-modifying proteins (RAMPs).
In preclinical studies, Cagrilintide has shown potent effects on:
Appetite suppression via central satiety pathways
Slowing gastric emptying and enhancing postprandial fullness
Body weight regulation through energy balance modulation
Synergistic activity with GLP-1 receptor agonists in metabolic studies
Its extended half-life and unique receptor activity profile make it valuable in metabolic and obesity research, particularly when combined with GLP-1 analogs like semaglutide or liraglutide.
Cagrilintide is a synthetic long-acting analog of amylin, a peptide hormone co-secreted with insulin by pancreatic β-cells. It acts as a non-selective amylin receptor agonist, binding primarily to calcitonin receptors and associated receptor activity-modifying proteins (RAMPs).
In preclinical studies, Cagrilintide has shown potent effects on:
Appetite suppression via central satiety pathways
Slowing gastric emptying and enhancing postprandial fullness
Body weight regulation through energy balance modulation
Synergistic activity with GLP-1 receptor agonists in metabolic studies
Its extended half-life and unique receptor activity profile make it valuable in metabolic and obesity research, particularly when combined with GLP-1 analogs like semaglutide or liraglutide.